Note 8 - Segment Information and Disaggregated Revenue

15 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 8. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe and Canada, for the three months ended September 30, 2021 and 2020 were $2,220 and $1,467, respectively.

Financial information relating to the three months ended September 30, 2021 and 2020 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2021	$	10,145	$	2,190	$	12,335	$	1,301	$	84	$	131
	2020		13,324		1,462		14,786		2,255		82		50
Other Nutraceutical Businesses	2021		386		30		416		123		1		-
	2020		381		5		386		118		1		3
Total Company	2021		10,531		2,220		12,751		1,424		85		131
	2020		13,705		1,467		15,172		2,373		83		53

	Total Assets as of
	September 30,		June 30,
	2021		2021
Contract Manufacturing	$	19,968	$	21,333
Other Nutraceutical Businesses		4,368		4,107
Total Company	$	24,336	$	25,440